title: Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
abstract: BACKGROUND
  The prognosis of advanced ovarian cancer is very poor, with about 15% of patients surviving at five years. Since most of these patients will relapse and/or progress while on therapy, effective salvage treatments are needed. A phase II trial was designed to evaluate the feasibility, toxicity, and response of a seven-day ambulatory continuous infusion of ifosfamide in patients with recurrent or chemoresistant advanced ovarian cancer.
  
  
  METHODS
  Nineteen patients with progressive ovarian cancer following a cisplatin-based induction chemotherapy were treated with continuous infusion ifosfamide with mesna at 1 g/m2/d and 400 mg/m2/d, respectively, for seven days every 28 days.
  
  
  RESULTS
  The overall response rate was 37%. Responses were observed both in patients who relapsed after induction chemotherapy (4/6) and in those who were resistant to cisplatin (3/13). Toxicity was mild and tolerable in these heavily pretreated patients.
  
  
  CONCLUSIONS
  Ifosfamide, when administered as a protracted continuous infusion is an active drug in ovarian cancer and can be safely administered in an out-patient setting. Toxicity is minor even in heavily pretreated patients. Responses are observed in cisplatin refractory ovarian cancer.
authors: Service de Médecine Oncologique, Section Médicale et Hospitalière, Paris, France.
authors: T
authors: T
authors: Dorval
authors: C
authors: C
authors: Soussain
authors: P
authors: P
authors: Beuzeboc
authors: E
authors: E
authors: Garcia-Giralt
authors: M
authors: M
authors: Jouve
authors: A
authors: A
authors: Livartowski
authors: V
authors: V
authors: Mosseri
authors: T
authors: T
authors: Palangié
authors: S
authors: S
authors: Scholl
authors: X
authors: X
authors: Sastre
authors: P
authors: P
authors: Pouillart
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000553:Ambulatory Care; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide